Insight into the different treatment options to reduce the risk of stroke in AF patients
The most common treatment for managing AF-related stroke risk is the use of anticoagulants, such as warfarin (Coumadin®) and novel oral anticoagulants (NOACs).
Warfarin and NOACs effectively reduce the risk of cardioembolic stroke, however they are not well tolerated by some patients and carry a risk for bleeding complications.
The limits of oral anticoagulants include:
- Risk of bleeding
- High rate of discontinuation (at 2 years, 50% of patients on VKA and 30% on NOAC treatment)1
- Interactions with certain foods and medications (warfarin)
- Frequent blood tests and dose adjustment (warfarin)
1. Martinez et al. Thromb Haemost 2015;114: In press.
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.